Chimeric: Media Thread, page-522

No question she's a great presenter. I also invested on the back of her presentation skills and the scientific potential a year ago. Got out about 6 months ago.

But now her presentations just annoy me.

- She made six separate mentions of positive / promising / encouraging early data
- She made two separate mentions of CHM being "First in Class"
- She noted the significant commercial potential of cell therapy
- She noted that CHM was the only listed cell-therapy company in Australia
- She noted the recent funding arrangement to facilitate their ongoing trials
- She observed that she "absolutely believed we're at a turning point" in the overall Biotech market
- She earned $1.75m in remuneration for 7-months work in FY2021
- She earned $2.69m in remuneration for FY2022.

She invested just $5,000 in the recent cap raise.

Its straight-out embarrassing and basically discredits the company.

And for the all that remuneration, she apparently watches the City of Hope and Penn University from the sidelines cheering "go faster, go faster" while managing a minuscule team.

For what actually gets delivered and for the speed of delivery, I reckon Hopper and his CEOs are the most overpaid executives on the ASX. $5m a quarter to watch other people do research. And for CHM's next trick, its going to "sponsor" (ie pay for) future trials, so they can "go faster" (ie spend more than $5m / quarter). Never fear, they just raised a bit under $5m, so no doubt as Jennifer says, "we're back in a position of investor confidence".